Citadel Advisors
PNT

Citadel Advisors’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Citadel Advisors’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,157,166
Closed -$14.4M – 15559
2023
Q3 		$14.4M Sell
2,157,166
-297,807
-12% -$2.48M ﹤0.01% 2244
2023
Q2 		$22.2M Sell
2,454,973
-733,055
-23% -$6.47M ﹤0.01% 1765
2023
Q1 		$23.2M Sell
3,188,028
-63,552
-2% -$471K 0.01% 1782
2022
Q4 		$23.7M Sell
3,251,580
-428,417
-12% -$3.18M 0.01% 1786
2022
Q3 		$28.4M Buy
3,679,997
+1,369,820
+59% +$11.6M 0.01% 1530
2022
Q2 		$15.7M Sell
2,310,177
-182,986
-7% -$1.4M ﹤0.01% 2109
2022
Q1 		$19.9M Buy
2,493,163
+37,359
+2% +$237K ﹤0.01% 1996
2021
Q4 		$13.8M Buy
2,455,804
+9,439
+0.4% +$70.8K ﹤0.01% 2547
2021
Q3 		$18.8M Buy
2,446,365
+1,946,365
+389% +$17.8M ﹤0.01% 2090
2021
Q2 		$4.81M Sell
500,000
-8,819
-2% -$89.7K ﹤0.01% 4532
2021
Q1 		$5.35M Buy
508,819
+8,660
+2% +$117K ﹤0.01% 4110
2020
Q4 		$6.98M Sell
500,159
-655
-0.1% -$9.09K ﹤0.01% 3124
2020
Q3 		$7.2M Buy
+500,814
New +$6.83M ﹤0.01% 2664

Other funds holding PNT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Citadel Advisors's PNT Position: Q4 2023 in Review

Citadel Advisors sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 2,157,166 shares — an estimated $14.4M sold.

Citadel Advisors first reported a position in PNT in Q3 2020 and held it in 13 quarters. The position peaked at $28.4M in Q3 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

  • Citadel Advisors reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 2,157,166 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $14.4M.
  • Citadel Advisors first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2020 and held it in 13 quarters.
  • Citadel Advisors's POINT Biopharma Global Inc. Common Stock position peaked at $28.4M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.